Steep dose-response relationship for stage I non-small cell lung cancer using hypo-fractionated high-dose irradiation by real-time tumor-tracking radiotherapy (RTRT)

Onimaru Rikiya; Fujino Masaharu; Yamazaki Koichi; Onodera Yuya; Taguchi Hiroshi; Katoh Norio; Hommura Fumihiro; Oizumi Satoshi; Nishimura Masaharu; Shirato Hiroki

Title	en Steep dose-response relationship for stage I non-small cell lung cancer using hypo-fractionated high-dose irradiation by real-time tumor-tracking radiotherapy (RTRT)
Creator	en Onimaru, Rikiya NRID 1000080374461 en Fujino, Masaharu en Yamazaki, Koichi en Onodera, Yuya en Taguchi, Hiroshi en Katoh, Norio NRID 1000080572495 en Hommura, Fumihiro en Oizumi, Satoshi NRID 1000010421968 en Nishimura, Masaharu NRID 1000000208224 en Shirato, Hiroki NRID 1000020187537
Accessrights	open access
Subject	Other en real-time tumor-tracking radiotherapy Other en stereotactic radiotherapy Other en lung cancer NDC 493
Description	Abstract en Purpose: To investigate the clinical outcomes of patients with pathologically proven, peripherally located, stage I non-small cell lung cancer (NSCLC) who received stereotactic body radiotherapy (SBRT) using real-time tumor tracking radiotherapy (RTRT) during the developmental period. Materials and Methods: Forty-one patients were admitted (T1, 25; T2, 16) from February 2000 to June 2005. A 5 mm lanning target volume (PTV) margin was added to the clinical target volume determined with computed tomography at the end of expiratory phase. The gating window ranged from ± 2 to 3 mm. The dose fractionation schedule was 40 or 48 Gy in 4 fractions within 7 days. The dose was prescribed at the center of the PTV, giving more than an 80% dose at the PTV periphery. Results: For 28 patients treated with 48 Gy in 4 fractions, the overall actuarial survival (OAS) at 3 years was 82% for stage IA and 32% for stage IB. For patients treated with 40Gy/4Fr/1wk, OAS at 3 years was 50% for stage IA and 0% for stage IB. There was a significant difference in local control between 40 and 48 Gy in stage IB (p=0.0015) but not in stage IA (p=0.5811). No serious radiation morbidity was observed in either dose schedule. Conclusion: Forty-eight Gy in 4 fractions in one week was found to be a safe and effective treatment for peripherally located, stage IA NSCLC. A steep dose-response curve between 40 and 48 Gy using a daily dose of 12 Gy delivered in one week was identified for stage IB NSCLC in SBRT using RTRT.
Publisher	en Elsevier
Date	Issued2008-02-01
Language	eng
Resource Type	journal article
Version Type	AM
Identifier	HDL http://hdl.handle.net/2115/33040
Relation	URI http://www.sciencedirect.com/science/journal/03603016 isVersionOf DOI https://doi.org/10.1016/j.ijrobp.2007.06.043 PMID 18029106
Journal	PISSN 0360-3016 NCID AA00680920 en International Journal of Radiation OncologyBiologyPhysics Volume Number70 Issue Number2 Page Start374 Page End381
File	fulltext Onimaru.pdf 186.53 KB (application/pdf) Issued2008-02-01
Oaidate	2023-07-26